In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including: The clinical implications of using DLL3 as a therapeutic target The impact of emerging DLL3-targeted therapies on evolving treatment paradigms How to incorporate DLL3-based treatments into clinical practice Presenters: Daniel Morgensztern, MD Professor of Medicine Clinical Director of Thoracic Oncology Washington University School of Medicine St Louis, Missouri Jonathan Strosberg, MD Professor Department of GI Oncology Moffitt Cancer Center and Research Institute Tampa, Florida Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. Link to full program: https://bit.ly/4mjNPfy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
